Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 12/20 | 0.41 |
| ▸ | HRH1 | P35367 | 12/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897714 | 0.85 | ACACB (0.40) | HRH2HRH1ACACB | |
| SCHEMBL2897713 | 0.85 | ACACB (0.40) | HRH2HRH1ACACB | |
| SCHEMBL2898414 | 0.83 | GPR119 (0.40) | HRH2HRH1GPR119KCNH2ACACB | |
| SCHEMBL2898412 | 0.83 | GPR119 (0.40) | HRH2HRH1GPR119KCNH2ACACB | |
| SCHEMBL8076548 | 0.83 | HRH2 (0.38) | HRH2HRH1GPR119DPP4KCNH2 | |
| SCHEMBL8073864 | 0.83 | DPP4 (0.41) | HRH2HRH1DPP4KCNH2DPP7 | |
| SCHEMBL8073128 | 0.74 | HRH2 (0.36) | HRH2HRH1ITGB3ITGA2BACACB | |
| SCHEMBL8073649 | 0.74 | ITGB3 (0.37) | HRH2HRH1ITGB3ITGA2B | |
| SCHEMBL8076479 | 0.74 | ITGB3 (0.49) | HRH2HRH1ITGB3ITGA2B | |
| SCHEMBL8072985 | 0.74 | ITGB3 (0.49) | HRH2HRH1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |